| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/24/2004 | WO2004052392A2 Cancer immunotherapy using polycomb proteins |
| 06/24/2004 | WO2004052379A1 Antidiarrheal composition |
| 06/24/2004 | WO2004052293A2 Recombinant vaccine against flavivirus infection |
| 06/24/2004 | WO2004052278A2 Escape mutants of newcastle disease virus as marker vaccines |
| 06/24/2004 | WO2004052276A2 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 06/24/2004 | WO2004052236A2 Methods and compositions for treatment of otitis media |
| 06/24/2004 | WO2004052233A2 Canine rankl and methods for preparing and using the same |
| 06/24/2004 | WO2004052186A2 Expressed genes that define the osteoclast phenotype |
| 06/24/2004 | WO2004041862A3 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| 06/24/2004 | WO2004041852A3 Hiv vaccine |
| 06/24/2004 | WO2004037286A3 Combination of a trioxopyrimidine compound inhibitor and an anti-tumor agent, and uses thereof |
| 06/24/2004 | WO2004031236A3 Therapeutic uspa1-derived peptides |
| 06/24/2004 | WO2004024883A3 PAKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE |
| 06/24/2004 | WO2004022716A3 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 06/24/2004 | WO2004011650A3 Antigens encoded by alternative reading frame from pathogenic viruses |
| 06/24/2004 | WO2003086311A3 Methods for treating tweak-related conditions |
| 06/24/2004 | WO2003083083A3 Methods of using flt3-ligand in immunization protocols |
| 06/24/2004 | WO2003076631A3 Genetic products differentially expressed in tumors and use thereof |
| 06/24/2004 | WO2003072716A3 Sequence analysis of the tetravalent rotavirus vaccine |
| 06/24/2004 | WO2003068800A3 Isolated peptides which bind to hla molecules and uses thereof |
| 06/24/2004 | WO2003063802A3 Mixed haptenized tumor cells and extracts and methods of treating or screening for cancer |
| 06/24/2004 | WO2003040165A3 Hla class i and ii binding peptides and their uses |
| 06/24/2004 | US20040123336 Using viral particles to improve effectiveness of gene transfer vehicle via inhibition of antigen presenting cells; somatic cell transformation and animal models for disease |
| 06/24/2004 | US20040123335 Using peptide mimetics to prevent or treat autoimmune diseases; immunotherapy |
| 06/24/2004 | US20040122217 Lectin compositions and methods for modulating an immune response to an antigen |
| 06/24/2004 | US20040122213 Chlamydia heat shock protein |
| 06/24/2004 | US20040121976 Anti-inflammatory vectors |
| 06/24/2004 | US20040121974 Vaccines comprising a bacteriophage which has been engineered to express an immunogenic protein/peptide and wherein the surface of the bacteriophage has not been modified to contain proteins/peptides designed to target the phage to receptors |
| 06/24/2004 | US20040121972 Methylenetetrahydrofolate reductase inhibitors and uses thereof |
| 06/24/2004 | US20040121956 For therapy of diseases in animals and for the control of insects that are injurious or harmful to plants or animals |
| 06/24/2004 | US20040121465 Optimization of gene sequences of virus-like particles for expression in insect cells |
| 06/24/2004 | US20040121433 P153 and P156 antigens for the immunodiagnosis of canine and human ehrlichioses and uses thereof |
| 06/24/2004 | US20040121372 Comprises receptors for advanced glycation endproduct polypeptides for use in diagnosis and treatment inflammation, infection, sepsis, autoimmune, atherosclerotic and nervous system disorders |
| 06/24/2004 | US20040121370 Novel composition and methods for the treatment of immune related diseases |
| 06/24/2004 | US20040121349 Novel 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor |
| 06/24/2004 | US20040121322 Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses |
| 06/24/2004 | US20040121317 HIV envelopolype peptides |
| 06/24/2004 | US20040120973 Coccidial vaccine and methods of making and using same |
| 06/24/2004 | US20040120972 equine abortion virus mutant |
| 06/24/2004 | US20040120970 vaccine is for administration in the submucosa of the labiae is an attenuated form of a horse pathogenic bacterium |
| 06/24/2004 | US20040120969 The pure isolate does not suffer from the disadvantages of potential batch to batch variation between substrains and provides a product which is easier to ensure will meet consistent quality guidelines |
| 06/24/2004 | US20040120966 polypeptide comprises a C domain identical to a polypeptide that is a competitive inhibitor of bacterial adhesion of pneumococcal |
| 06/24/2004 | US20040120964 Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses |
| 06/24/2004 | US20040120962 Modulation of immune responses to foreign antigens expressed by recombinant attenuated bacterial vectors |
| 06/24/2004 | US20040120960 initial dosing of a therapeutically effective amount of an LFA-1 antagonist, followed by a subsequent intermittent dosing of a therapeutically effective amount of an LFA-1 antagonist |
| 06/24/2004 | US20040120958 Modified antibodies to prostate-specific membrane antigen and uses thereof |
| 06/24/2004 | US20040120957 Use of A33 antigens JAM-it |
| 06/24/2004 | US20040120953 Antagonists of HMG1 for treating inflammatory conditions |
| 06/24/2004 | US20040120952 Anti-TNF antibodies and peptides of human tumor necrosis factor |
| 06/24/2004 | US20040120945 Cell surface molecule mediating cell adhesion and signal transmission |
| 06/24/2004 | US20040120935 Genetically modified yt cell line and use thereof |
| 06/24/2004 | US20040120928 Composite oncolytic herpes virus vectors |
| 06/24/2004 | US20040120926 Reactive oxygen metabolite inhibitors for use in compositions and methods of treatment |
| 06/24/2004 | US20040120924 Treatment and prevention of immunodeficiency virus infection by administration of non-pyrogenic derivatives of lipid A |
| 06/24/2004 | US20040120896 Buccal aerosol sprays or capsules using polar and non-polar solvent which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect |
| 06/24/2004 | US20040120895 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| 06/24/2004 | CA2509539A1 Method of diagnosis,treatment and useful agents for conditions characterised by modulation in the level of activin .beta.c |
| 06/24/2004 | CA2509387A1 Peptide oligomers for use as hiv vaccines |
| 06/24/2004 | CA2509197A1 Plasmodium falciparum antigens and methods of use |
| 06/24/2004 | CA2509058A1 Administration of dendritic cells partially matured in vitro for the treatment of tumors |
| 06/24/2004 | CA2508847A1 Central nervous system damage |
| 06/24/2004 | CA2508773A1 Canine rankl and methods for preparing and using the same |
| 06/24/2004 | CA2508762A1 Methods and compositions for treatment of otitis media |
| 06/24/2004 | CA2508348A1 Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy |
| 06/23/2004 | EP1431311A1 Immunotherapy of B-cell malignancies using anti-CD22 and anti-CD20 antibodies in combination |
| 06/23/2004 | EP1431310A1 RECOMBINANT ANTI−OSTEOPONTIN ANTIBODY AND USE THEREOF |
| 06/23/2004 | EP1430904A1 Desensitizers |
| 06/23/2004 | EP1430305A2 A method and kit for the measurement of the activation of basophils induced by allergen to determine hypersensitivity |
| 06/23/2004 | EP1430152A2 Gene and protein relating to hepatocellular carcinoma |
| 06/23/2004 | EP1430137A2 Porcine adenovirus e1 and e4 regions |
| 06/23/2004 | EP1430134A2 Hdv nucleic acid molecules, fragments and applications thereof |
| 06/23/2004 | EP1430132A2 Methods of using 33751, a human potassium channel family member |
| 06/23/2004 | EP1430129A2 Asip-related proteins |
| 06/23/2004 | EP1430127A1 Polynucleotide fragments of an infectious human endogenous retrovirus |
| 06/23/2004 | EP1430125A2 Sperm-specific cation channel, and uses therefor |
| 06/23/2004 | EP1430085A1 Leukocyte inactivation module |
| 06/23/2004 | EP1430077A2 Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections |
| 06/23/2004 | EP1430076A2 Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same |
| 06/23/2004 | EP1429845A2 Treatment or prophylaxis of insulin-producing cell graft rejection |
| 06/23/2004 | EP1429805A2 Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass |
| 06/23/2004 | EP1429804A2 Inhibitors of costimulation by ox40 and their use against infectious diseases |
| 06/23/2004 | EP1429803A2 Anti-coronavirus vaccine |
| 06/23/2004 | EP1429801A1 Neuropilin as a novel therapeutic target for modulation of immune reponses |
| 06/23/2004 | EP1429800A2 Vaccine and method for treatment of motor neurone diseases |
| 06/23/2004 | EP1429797A2 Diagnosis and treatment of malignant neoplasms |
| 06/23/2004 | EP1429785A1 Imunogenic conjugate of carbohydrate haptens and aggregated protein carrier |
| 06/23/2004 | EP1429623A1 Delivery of disease control in aquaculture and agriculture using nutritional feeds containing bioactive proteins produced by viruses |
| 06/23/2004 | EP1429615A1 Oral vaccines |
| 06/23/2004 | EP1071438B1 Stabilised herpesvirus preparation |
| 06/23/2004 | EP1068323B1 Recombinant major allergen of the pollen of artemisia vulgaris (mugwort) |
| 06/23/2004 | EP0842042B1 Improved methods for the manufacture of magnetically responsive particles |
| 06/23/2004 | EP0750505B1 Immunotherapy of cancer with allogeneic lymphocytes |
| 06/23/2004 | EP0646176B1 Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria |
| 06/23/2004 | CN1507452A Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides |
| 06/23/2004 | CN1507355A Combination therapy using anti-EGFR antibodies and anti-hormonal agents |
| 06/23/2004 | CN1507354A Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists |
| 06/23/2004 | CN1507353A Compositions for use in treating IGE-associated disorders |
| 06/23/2004 | CN1506376A Embedded CD25-resisting monoclonal antibody and its coding sequence and application |
| 06/23/2004 | CN1506115A Calmette-Guerin bacillus prepn |
| 06/23/2004 | CN1154742C Recombinant MVA virus, and the use thereof |